Endpoints News 生物医药· Anna Brown·· 2 小时前AI 评分25
Celldex 停止eczema治疗药物barzolvolimab的临床试验
Celldex culls eczema study after Phase 2 failure
AI 导读
Celldex Therapeutics 停止了其单克隆抗体药物barzolvolimab用于治疗eczema的临床试验,该药物在中期试验中失败。
正文
Celldex Therapeutics is dropping its monoclonal antibody as a therapy for eczema after the drug flunked a mid-stage study.
The drug, called barzolvolimab, failed to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news